Published in J Heart Lung Transplant on October 01, 2012
Dealing with surgical left ventricular assist device complications. J Thorac Dis (2015) 0.90
When the Battle is Lost and Won: Delayed Chest Closure After Bilateral Lung Transplantation. Med Sci Monit Basic Res (2015) 0.75
Active Clearance of Chest Tubes Reduces Re-Exploration for Bleeding After Ventricular Assist Device Implantation. ASAIO J (2016) 0.75
Use of a continuous-flow device in patients awaiting heart transplantation. N Engl J Med (2007) 7.15
Fifth INTERMACS annual report: risk factor analysis from more than 6,000 mechanical circulatory support patients. J Heart Lung Transplant (2013) 4.60
Extended mechanical circulatory support with a continuous-flow rotary left ventricular assist device. J Am Coll Cardiol (2009) 4.03
Clinical management of continuous-flow left ventricular assist devices in advanced heart failure. J Heart Lung Transplant (2010) 4.00
Continuous flow left ventricular assist device improves functional capacity and quality of life of advanced heart failure patients. J Am Coll Cardiol (2010) 3.63
Risk of worsening renal function with nesiritide in patients with acutely decompensated heart failure. Circulation (2005) 3.48
Use of an intrapericardial, continuous-flow, centrifugal pump in patients awaiting heart transplantation. Circulation (2012) 3.24
Results of the post-U.S. Food and Drug Administration-approval study with a continuous flow left ventricular assist device as a bridge to heart transplantation: a prospective study using the INTERMACS (Interagency Registry for Mechanically Assisted Circulatory Support). J Am Coll Cardiol (2011) 3.06
Prognostic significance of mitral regurgitation and tricuspid regurgitation in patients with left ventricular systolic dysfunction. Am Heart J (2002) 2.95
The Fourth INTERMACS Annual Report: 4,000 implants and counting. J Heart Lung Transplant (2012) 2.69
INTERMACS profiles of advanced heart failure: the current picture. J Heart Lung Transplant (2009) 2.49
Impact of mitral valve annuloplasty on mortality risk in patients with mitral regurgitation and left ventricular systolic dysfunction. J Am Coll Cardiol (2005) 2.38
Predicting survival in patients receiving continuous flow left ventricular assist devices: the HeartMate II risk score. J Am Coll Cardiol (2012) 2.37
The right ventricular failure risk score a pre-operative tool for assessing the risk of right ventricular failure in left ventricular assist device candidates. J Am Coll Cardiol (2008) 2.37
Autologous skeletal myoblasts transplanted to ischemia-damaged myocardium in humans. Histological analysis of cell survival and differentiation. J Am Coll Cardiol (2003) 2.35
Cardiac improvement during mechanical circulatory support: a prospective multicenter study of the LVAD Working Group. Circulation (2007) 2.34
Right ventricular failure in patients with the HeartMate II continuous-flow left ventricular assist device: incidence, risk factors, and effect on outcomes. J Thorac Cardiovasc Surg (2010) 2.29
INTERMACS database for durable devices for circulatory support: first annual report. J Heart Lung Transplant (2008) 2.17
Discharge education improves clinical outcomes in patients with chronic heart failure. Circulation (2005) 2.12
Third INTERMACS Annual Report: the evolution of destination therapy in the United States. J Heart Lung Transplant (2011) 2.01
HeartWare ventricular assist system for bridge to transplant: combined results of the bridge to transplant and continued access protocol trial. J Heart Lung Transplant (2013) 1.96
Second INTERMACS annual report: more than 1,000 primary left ventricular assist device implants. J Heart Lung Transplant (2010) 1.93
Continuous-flow devices and percutaneous site infections: clinical outcomes. J Heart Lung Transplant (2012) 1.90
The development of aortic insufficiency in left ventricular assist device-supported patients. Circ Heart Fail (2010) 1.87
Left ventricular assist device therapy improves utilization of donor hearts. J Am Coll Cardiol (2002) 1.85
Renal and hepatic function improve in advanced heart failure patients during continuous-flow support with the HeartMate II left ventricular assist device. Circulation (2009) 1.84
The cost of medical management in advanced heart failure during the final two years of life. J Card Fail (2008) 1.71
Low thromboembolism and pump thrombosis with the HeartMate II left ventricular assist device: analysis of outpatient anti-coagulation. J Heart Lung Transplant (2009) 1.62
Infection in permanent circulatory support: experience from the REMATCH trial. J Heart Lung Transplant (2004) 1.56
Long-term mechanical circulatory support (destination therapy): on track to compete with heart transplantation? J Thorac Cardiovasc Surg (2012) 1.55
There is plenty for everyone: transection of the infracardiac inferior vena cava during organ recovery. Liver Transpl (2012) 1.48
Model for end-stage liver disease score predicts left ventricular assist device operative transfusion requirements, morbidity, and mortality. Circulation (2010) 1.44
Pump replacement for left ventricular assist device failure can be done safely and is associated with low mortality. Ann Thorac Surg (2012) 1.41
Safety and feasibility of autologous myoblast transplantation in patients with ischemic cardiomyopathy: four-year follow-up. Circulation (2005) 1.32
Vitamin D and cardiovascular disease. Pharmacotherapy (2009) 1.28
Hemodynamic and exercise performance with pulsatile and continuous-flow left ventricular assist devices. Circulation (2007) 1.21
Continuous flow left ventricular assist device outcomes in commercial use compared with the prior clinical trial. Ann Thorac Surg (2011) 1.21
Device exchange after primary left ventricular assist device implantation: indications and outcomes. Ann Thorac Surg (2012) 1.18
Recommendations for the use of mechanical circulatory support: device strategies and patient selection: a scientific statement from the American Heart Association. Circulation (2012) 1.16
Post-cardiac transplant survival after support with a continuous-flow left ventricular assist device: impact of duration of left ventricular assist device support and other variables. J Thorac Cardiovasc Surg (2010) 1.11
Post-operative heparin may not be required for transitioning patients with a HeartMate II left ventricular assist system to long-term warfarin therapy. J Heart Lung Transplant (2010) 1.11
Barriers to constraining health care cost growth. Health Aff (Millwood) (2004) 1.07
Validation of peak exercise oxygen consumption and the Heart Failure Survival Score for serial risk stratification in advanced heart failure. Am J Cardiol (2005) 1.05
Spironolactone-induced renal insufficiency and hyperkalemia in patients with heart failure. Am Heart J (2004) 1.05
The prevalence and pattern of complementary and alternative supplement use in individuals with chronic heart failure. J Card Fail (2005) 1.04
Prospective, multicenter study of ventricular assist device infections. Circulation (2013) 1.03
Myocardial proinflammatory cytokine expression and left ventricular remodeling in patients with chronic mitral regurgitation. Circulation (2003) 1.03
Short- and long-term survival of patients transferred to a tertiary care center on temporary extracorporeal circulatory support. Ann Thorac Surg (2009) 1.01
Surgical management of patients in the REMATCH trial. Ann Thorac Surg (2003) 1.00
Nosocomial infections in left ventricular assist device recipients. Clin Infect Dis (2002) 0.99
Low operative mortality with implantation of a continuous-flow left ventricular assist device and impact of concurrent cardiac procedures. Circulation (2009) 0.99
Left ventricular assist device-associated infections. Infect Dis Clin North Am (2012) 0.98
A call for guidance in the use of left ventricular assist devices in older adults. J Am Geriatr Soc (2012) 0.98
Anterior leaflet repair with patch augmentation for mitral regurgitation. Ann Thorac Surg (2005) 0.95
ACCF/AHA/ACP/HFSA/ISHLT 2010 clinical competence statement on management of patients with advanced heart failure and cardiac transplant: a report of the ACCF/AHA/ACP Task Force on Clinical Competence and Training. J Am Coll Cardiol (2010) 0.93
Patient selection for left ventricular assist device therapy. Ann Thorac Surg (2003) 0.92
Atrial reduction plasty Cox maze procedure: extended indications for atrial fibrillation surgery. Ann Thorac Surg (2004) 0.92
Interaction study between digoxin and a preparation of hawthorn (Crataegus oxyacantha). J Clin Pharmacol (2003) 0.92
Heart failure survival score continues to predict clinical outcomes in patients with heart failure receiving beta-blockers. J Heart Lung Transplant (2004) 0.91
Roseomonas infection associated with a left ventricular assist device. Infect Control Hosp Epidemiol (2003) 0.90
Determinants of postinfarction ventricular tachycardia. Circ Arrhythm Electrophysiol (2010) 0.90
Influence of age on outcomes in patients undergoing mitral valve replacement. Ann Thorac Surg (2002) 0.90
Beating heart surgery via right thoracotomy for reoperative mitral valve surgery: a safe and effective operative alternative. J Thorac Cardiovasc Surg (2011) 0.90
Risk of death associated with nesiritide in patients with acutely decompensated heart failure. JAMA (2006) 0.89
Hawthorn Extract Randomized Blinded Chronic Heart Failure (HERB CHF) trial. Eur J Heart Fail (2009) 0.89
Survival after biventricular assist device implantation: an analysis of the Interagency Registry for Mechanically Assisted Circulatory Support database. J Heart Lung Transplant (2011) 0.89
Bridge to transplantation: current outcomes. J Card Surg (2010) 0.89
Preoperative atrial fibrillation increases risk of thromboembolic events after left ventricular assist device implantation. Ann Thorac Surg (2013) 0.88
Quantifying the effect of cardiorenal syndrome on mortality after left ventricular assist device implant. J Heart Lung Transplant (2013) 0.88
Left thoracotomy for multiple-time redo mitral valve surgery using on-pump beating heart technique. Ann Thorac Surg (2008) 0.88
Extracorporeal mechanical circulatory assist. Cardiol Clin (2003) 0.86
The effect of Crataegus oxycantha Special Extract WS 1442 on clinical progression in patients with mild to moderate symptoms of heart failure. Eur J Heart Fail (2008) 0.86
ACCF/AHA/ACP/HFSA/ISHLT 2010 clinical competence statement on management of patients with advanced heart failure and cardiac transplant: a report of the ACCF/AHA/ACP Task Force on Clinical Competence and Training. Circulation (2010) 0.86
Heart failure prognostic models: why bother? Circ Heart Fail (2012) 0.85
Neurocognitive assessments in advanced heart failure patients receiving continuous-flow left ventricular assist devices. J Heart Lung Transplant (2009) 0.84
Feasibility and safety of autologous myoblast transplantation in patients with ischemic cardiomyopathy. Cell Transplant (2005) 0.83
Predictors of in-hospital mortality in children after long-term ventricular assist device insertion. J Am Coll Cardiol (2011) 0.82
Relation of body mass index to mortality after development of heart failure due to acute coronary syndrome. Am J Cardiol (2009) 0.82
Endoscopic findings and clinical outcomes in ventricular assist device recipients with gastrointestinal bleeding. Dig Dis Sci (2011) 0.82
Baseline albumin is associated with worsening renal function in patients with acute decompensated heart failure receiving continuous infusion loop diuretics. Pharmacotherapy (2013) 0.81
Prognostic impact of the addition of peak oxygen consumption to the Seattle Heart Failure Model in a transplant referral population. J Heart Lung Transplant (2012) 0.81
PKCβII modulation of myocyte contractile performance. J Mol Cell Cardiol (2012) 0.81